Chelation therapy uses a prescription drug that binds a particular metal so the complex can be eliminated. It is legitimate treatment for selected confirmed poisonings, but “chelation” is not a general cleanse and no single agent removes every toxin.
Diagnosis comes before treatment
Testing should be selected from a credible exposure history, symptoms, timing, and metal-specific toxicokinetics. Venous blood lead, speciated urine arsenic, or blood versus urine mercury may be appropriate in different situations. Broad hair panels and urine collected after a chelator (“provoked” or “challenge” testing) do not establish poisoning and can drive unnecessary treatment.
Agents are not interchangeable
Calcium disodium EDTA is used for lead poisoning under defined circumstances and can injure kidneys or deplete essential metals. It must not be confused with disodium EDTA, which can cause fatal hypocalcemia if administered incorrectly. Oral succimer has an FDA-approved lead indication in children with specified blood lead levels. Dimercaprol, deferoxamine, deferasirox, penicillamine, and other agents have distinct indications and toxicities. DMPS is not an FDA-approved drug in the United States.
Exposure control is essential
Chelation cannot substitute for removing contaminated paint, dust, water, supplements, occupational sources, cookware, or other exposure. Levels can rebound from ongoing exposure or redistribution from tissue stores.
Cardiovascular and wellness use
EDTA-based infusion protocols have been studied after myocardial infarction. TACT reported a modest composite signal, but TACT2 did not show benefit on its primary cardiovascular endpoint. Chelation is not routine coronary disease or anti-aging therapy and must not replace lipid, blood-pressure, diabetes, smoking, or antiplatelet management.